Study reveals low adoption of recommended smart inhaler therapy for asthma

FHS
May 22, 2024
3:51 am

Only 14.5 percent of adult patients with moderate or severe asthma are prescribed the recommended SMART combination inhaler regimen and over 40 percent of academic pulmonary and allergy clinicians have not adopted this optimal therapy, according to research published at the ATS 2024 International Conference.

Vistagen’s positive PhIII for social anxiety nasal spray pushes stock price up 1,000+%

San Francisco-based Vistagen saw its stock soar more than 1,000% at one point on Monday after unveiling positive topline results from a Phase III trial

August 8, 2023

Researchers identify key genetic players in dopamine signaling using transparent worms With The Help Of A Tin…

Dopamine, a powerful brain chemical and neurotransmitter, is a key regulator of many important functions such as attention, experiencing pleasure and reward, and coordinating movement.

August 12, 2024

Chemoimmunotherapy Improves Pathologic Outcomes in Gastroesophageal Carcinoma

Adding immunotherapy to neoadjuvant chemotherapy for resectable gastroesophageal cancer led to higher rates of disease downstaging and pathologic complete response (pCR), an exploratory analysis of

November 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.